good to see an update and another tick for safety.
The clincal work seems to be great with CHM - nailing FDA approvals and clearing safety hurdles regularly. Shouldn't be taken for granted.
I cannot fault this aspect of the company.
Great to hear the below from the COO - added value to the announcement.
“It has been great to see the progress of this clinical trial for these AML patients” said Dr
Rebecca McQualter, Chief Operating Officer of Chimeric.
Ann: Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.747M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $27.16K | 8.958M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 69 | 66853948 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 94845096 | 28 |
View Market Depth
| Last trade - 16.10pm 29/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |